Payment brings the total fees received this year under smallpox vaccine contract up to $100 million.

Bavarian Nordic reports that it has reached another milestone in its agreement with the U.S. government and will thus receive $25 million. In June, the HHS contracted the firm to manufacture and deliver 20 million doses of its smallpox vaccine in a deal potentially worth $1.6 billion.

This year, Bavarian Nordic has received $100 million in relation to this deal. The firm was reportedly paid $50 million in advance. It also received another $25 million milestone fee just three weeks ago.

Next year, Bavarian Nordic expects to receive yet another milestone payment of $25 million.
Imvamune is based on the Modified Vaccinia Ankara virus, a live virus but one that does not replicate in the body, according to the company.

Previous articleScientists Find Link between Cellular Defense Processes Inside and Outside Cells
Next articleThermo Fisher Scientific Gobbles Up German Firm